Skip to main content

Table 2 Genes significantly upregulated or downregulated by hypoxia and/or dimethyloxalylglycine in human rheumatoid arthritis fibroblast-like synoviocytes

From: Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA

Genes that change only in response to hypoxia

Genes that change only in response to DMOG

Genes that change in response to hypoxia and DMOG

TGF-β1 (2*)

NRP2 (-2*)

VEGF (8*/31*)

HPSE (-2*)

ID3 (-3*)

PLAU (-2*/-2*)

FIGF (-2*)

EFNB2 (5*)

LEP (108***/85***)

CXCL-5 (-2*)

CCL2 (-4*)

HIF1A (-2*/-2*)

CCL-11 (-9*)

 

HAND2 (-2*/-6*)

  

EFNA3 (2*/9*)

  

ANGPTL4 (12**/48**)

  1. Genes significantly upregulated or downregulated by a factor ≥2. Genes from Figure 1b,c that change following 24 hours of hypoxia and in response to stimulation with the hypoxia-inducible factor activator dimethyloxalylglycine (DMOG) in rheumatoid arthritis fibroblast-like synoviocytes from five and three patients, respectively. Data presented as mean fold-change. Genes that changed significantly (P < 0.05) by a factor ≥2-fold were analysed by paired Student's t test comparing ΔCt values: *P < 0.05, **P < 0.001, ***P < 0.001. ANGPTL, angiopoietin-like; EFNA3, ephrin A3;EFNB2, ephrin B2; FIGF, C-fos-induced growth factor (VEGF D); HAND2, Heart and neural crest derivatives expressed 2; HPSE, heparanase; ID3, inhibitor of DNA-binding 3, dominant negative helix-loop-helix protein; LEP, leptin; NRP2, neuropillin 2; PLAU, plasminogen activator urokinase; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us